3 Dividend-Paying Pharmaceutical Stocks Rated Strong Buy in the POWR Ratings

This post was originally published on this site


Moreover, the industry is expected to grow going forward as the population ages and chronic diseases rise. According to a LINCHPIN report, the pharmaceutical industry is expected to increase to $1.5 trillion by 2023.

Therefore, we think dividend-paying quality pharmaceutical stocks Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (MRK), and Bristol-Myers Squibb Company (NYSE:BMY) could be solid additions to one’s portfolio to secure a steady income stream. They each have an overall Strong Buy rating in our POWR Ratings system.

Continue reading on StockNews